Comparative study of efficacy of Gunja Beeja lepa and Shunthi Churna lepa in Inflammatory Conditions of Arthritis - A Randomized Controlled Single Blinded Clinical Study
Keywords:Gunja Beeja lepa, Arthritis, Life style disorders, Shunthi, Disease Activity Score
Background: Life style disorders are an emerging problem in India where various types of arthritis are hampering the routine activities of people due to severe pain and inflammation. In such circumstances, everybody wants quick relief with the symptoms. Visha dravya used in Ayurveda are known for their quick action. Gunja (Abrus precatorius Linn) is a visha indicated in various diseases for internal and external use. Objectives: A randomized clinical study was conducted to assess the efficacy of Gunja beeja lepa to manage the local inflammatory conditions of Arthritis in comparison with a standard anti-inflammatory Ayurvedic drug Shunthi (Zingiber officinalis Linn) to provide a potent anti-inflammatory drug for the purpose of clinical practice. Material and methods: Patients suffering from transient mono or bi-arthropathies of knee were applied Gunja beeja lepa in comparison with local application of standard anti-inflammatory Ayurvedic drug Shunthi. Assessment was done with the help of Disease Activity Score (DAS-28-3) including three variables viz; tender joint score (Range 0-28), Swollen Joint Count (Range 0-28) and Erythrocyte sedimentation rate. Statistical comparisons were performed by both paired, unpaired student’s t test by using Sigma stat software (version 3.1) for both the experimental the groups at p<0.05 (level of significance). Result: Intervention with Gunja beeja lepa was statistically significant (p=0.003) in comparison with the intervention with Shunthi churna lepa. Conclusion: Gunja Beeja lepa is effective in comparison with standard anti-inflammatory Ayurvedic drug Shunthi in inflammatory conditions of Arthritis.
How to Cite
The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.
This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.
The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.